French vaccine maker Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles.

A new FDA approval for a first-in-class drug has vaulted Otsuka into the IgAN disease space, an increasingly competitive field targeted by multiple biopharma companies such as Novartis and Vertex.

The company filed its bid for a 7.2 mg Wegovy formulation using its National Priority Voucher from the FDA, which promises to accelerate a regulatory review to around one to two months.

The U.S. has revealed price reductions for the second round of prescription drugs negotiated by Medicare through the Inflation Reduction Act (IRA). Headlining the list of 15 treatments that will undergo price reductions in 2027 are Novo Nordisk’s semaglutide products, Ozempic and Wegovy.

More than 30 agents conducted a surprise raid of Sanofi’s headquarters in Paris on Tuesday morning as part of a tax fraud investigation, according to a report from French newspaper Le Monde.

The FDA signed off on Imfinzi as the first immunotherapy that can treat certain patients with early-stage stomach cancer both before and after surgery, marking the drug’s third perioperative nod.